.Gamma.-Cyclodextrin, 6A,6B,6C,6D,6E,7F,6G,6H-Octakis-S-(2-Carboxyethyl)-6A,6B,6C,6D,6E,7F,6G,6H-Octathio-
Respiratory System Disorder
Ziekenhuis Oost-LimburgSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Respiratory System Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Nanfang Hospital, Southern Medical University | Phase 3 | BB |
Neostigmine Coastal Anesthesiology Consultants | Phase 4 | BB |
Rocuronium Ion Ziekenhuis Oost-Limburg | Phase 4 | BB |
Cis-Diamminedichloroplatinum Ii Nanfang Hospital, Southern Medical University | Phase 3 | BB |
Pralsetinib, Trans- Hoffmann-La Roche | Phase 3 | BB |
View all 31 →
Same molecule, other indications
.Gamma.-Cyclodextrin, 6A,6B,6C,6D,6E,7F,6G,6H-Octakis-S-(2-Carboxyethyl)-6A,6B,6C,6D,6E,7F,6G,6H-Octathio- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →